A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 18-0685

More information available at ClinicalTrials.gov: NCT03504488

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers